Epirubicin (Slovenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Epirubicin" in Slovenian language version.

refsWebsite

Global rank Slovenian rank

6doi.org

2^nd place

5^th place

5nih.gov

4^th place

8^th place

2cbz.si

low place

607^th place

2web.archive.org

1^st place

2^nd place

1termania.net

low place

34^th place

1archive.org

6^th place

9^th place

archive.org

Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, in sod. (april 2003). »Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741«. Journal of Clinical Oncology. 21 (8): 1431–1439. doi:10.1200/JCO.2003.09.081. PMID 12668651.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)

cbz.si

http://www.cbz.si/cbz/bazazdr2.nsf/o/9FAA689EDCEEC5C5C12579EC00200185/$File/s-024635.pdf Arhivirano 2023-05-06 na Wayback Machine. , Povzetek glavnih značilnosti zdravila Epirubicin Teva 2 mg/ml raztopina za injiciranje ali infundiranje, vpogled: 6. 5. 2023.
http://www.cbz.si/cbz/bazazdr2.nsf/o/FBE4C0B81072C1DFC12579C2003F6270/$File/s-026684.pdf Arhivirano 2023-05-06 na Wayback Machine. Povzetek glavnih značilnosti zdravila Epirubicin Ebewe 2 mg/ml koncentrat za raztopino za infundiranje, vpogled: 6. 5. 2023.

doi.org

Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, in sod. (april 2003). »Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741«. Journal of Clinical Oncology. 21 (8): 1431–1439. doi:10.1200/JCO.2003.09.081. PMID 12668651.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Plosker, G.L., Faulds, D. Epirubicin. Drugs 45, 788–856 (1993). https://doi.org/10.2165/00003495-199345050-00011.
Glück S (2005). »Adjuvant chemotherapy for early breast cancer: optimal use of epirubicin«. The Oncologist. 10 (10): 780–91. doi:10.1634/theoncologist.10-10-780. PMID 16314288.
Mouridsen HT, Alfthan C, Bastholt L, Bergh J, Dalmark M, Eksborg S, in sod. (Januar 1990). »Current status of epirubicin (Farmorubicin) in the treatment of solid tumours«. Acta Oncologica. 29 (3): 257–285. doi:10.3109/02841869009089998. PMID 2194531.
Coukell AJ, Faulds D (Marec 1997). »Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer«. Drugs. 53 (3): 453–482. doi:10.2165/00003495-199753030-00008. PMID 9074845.
Cersosimo RJ, Hong WK (Marec 1986). »Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue«. Journal of Clinical Oncology. 4 (3): 425–439. doi:10.1200/JCO.1986.4.3.425. PMID 3005521.

nih.gov

pubmed.ncbi.nlm.nih.gov

Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, in sod. (april 2003). »Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741«. Journal of Clinical Oncology. 21 (8): 1431–1439. doi:10.1200/JCO.2003.09.081. PMID 12668651.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Glück S (2005). »Adjuvant chemotherapy for early breast cancer: optimal use of epirubicin«. The Oncologist. 10 (10): 780–91. doi:10.1634/theoncologist.10-10-780. PMID 16314288.
Mouridsen HT, Alfthan C, Bastholt L, Bergh J, Dalmark M, Eksborg S, in sod. (Januar 1990). »Current status of epirubicin (Farmorubicin) in the treatment of solid tumours«. Acta Oncologica. 29 (3): 257–285. doi:10.3109/02841869009089998. PMID 2194531.
Coukell AJ, Faulds D (Marec 1997). »Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer«. Drugs. 53 (3): 453–482. doi:10.2165/00003495-199753030-00008. PMID 9074845.
Cersosimo RJ, Hong WK (Marec 1986). »Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue«. Journal of Clinical Oncology. 4 (3): 425–439. doi:10.1200/JCO.1986.4.3.425. PMID 3005521.

termania.net

https://www.termania.net/slovarji/slovenski-medicinski-slovar/5514233/epirubicin?query=Epirubicin&SearchIn=All, Slovenski medicinski e-slovar, vpogled: 6. 5. 2023.

web.archive.org

http://www.cbz.si/cbz/bazazdr2.nsf/o/9FAA689EDCEEC5C5C12579EC00200185/$File/s-024635.pdf Arhivirano 2023-05-06 na Wayback Machine. , Povzetek glavnih značilnosti zdravila Epirubicin Teva 2 mg/ml raztopina za injiciranje ali infundiranje, vpogled: 6. 5. 2023.
http://www.cbz.si/cbz/bazazdr2.nsf/o/FBE4C0B81072C1DFC12579C2003F6270/$File/s-026684.pdf Arhivirano 2023-05-06 na Wayback Machine. Povzetek glavnih značilnosti zdravila Epirubicin Ebewe 2 mg/ml koncentrat za raztopino za infundiranje, vpogled: 6. 5. 2023.